Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

{
  "signal_id": "f3362b97-939d-49e7-3cbf-eda15fb34c04",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-18T14:51:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/18/3364794/0/en/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-pmr.html",
    "title": "Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)",
    "excerpt": "Basel, September 18, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx ® (secukinumab) in polymyalgia rheumatica (PMR).⁸ The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper.⁸ If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for people living with PMR, a disease with very limited advanced treatment options.¹˒³⁻⁷",
    "product": "Cosentyx",
    "summary": "Novartis's drug Cosentyx® (secukinumab) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending it for marketing authorization to treat polymyalgia rheumatica (PMR).",
    "location": "Basel, Switzerland",
    "planning": true,
    "confidence": 0.95,
    "product_data": {
      "name": "Cosentyx",
      "full_text": "Cosentyx ® (secukinumab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-18T14:51:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-18",
    "article_sentence": "Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx ® (secukinumab) in polymyalgia rheumatica (PMR)."
  }
}

curl https://signals.autobound.ai/v1/signals/f3362b97-939d-49e7-3cbf-eda15fb34c04 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novartis.com","limit":20}'